The PSOLVE+ community on Sosido will be wrapping up at the end of June 2022. It has been a pleasure to work with you!

Dear PSOLVE+ Members,

The PSOLVE+ community on Sosido will be wrapping at the end of this month, and you will receive your final PSOLVE+ Sosido email digest on Wednesday, June 29. For those of you who are members of other communities on Sosido (e.g. HIVE) you will continue to receive a weekly Sosido email digest with content from your other communities, and we will continue to track and feature your publications for your other communities.

Thank you for the privilege of serving you, and thank you to Novartis Canada for their generous support of this initiative.


The Surface, Issue #15 is now out! We feature a shared clinical pathway to screen and identify non-alcoholic fatty liver disease in psoriasis patients, a study of fractional laser-assisted treatment of nail psoriasis, a case report of methotrexate-associated lymphoproliferative disease and a review of the role of S aureus colonization in IgE-mediated disease

The Surface Issue #15, June 2022 edition, was sent to all PSOLVE+ members by email on Monday, June 20th and can be accessed online here.

To view all issues of The Surface, go to psolve.org/the-surface

The Surface, Issue #14 is now available! We feature a report on desensitization following hypersensitivity to mRNA vaccines, commentary on new data for JAKi in HS, and review management strategies for pediculosis capitis infestation. We also highlight a new Canadian expert panel report on the use of systemic psoriasis treatment in people living with HIV and a review of the evidence and mechanism of action for tars in psoriasis treatment.

The Surface Issue #14, June 2022 edition, was sent to all PSOLVE+ members by email on Monday, June 6th and can be accessed online here.

To view all issues of The Surface, go to psolve.org/the-surface

The Surface, Issue #13 is now available! We highlight publications on HS and PsO in pregnancy, the association between isotretinoin dose and hair loss, hormonal IUD use and dermatologic adverse effects, patients with PEG allergy receiving mRNA vaccines, and novel aryl hydrocarbon receptor-modulating agents in psoriasis.

The Surface Issue #13, May 2022 edition, was sent to all PSOLVE+ members by email on Monday, May 9th and can be accessed online here.

To view all issues of The Surface, go to psolve.org/the-surface

The Surface, Issue #12 is now available! We feature publications on the association between psoriasis and non-alcoholic fatty liver disease, questions from a Canadian PsA tool to screen for psoriasis, clascoterone 1% cream for acne vulgaris, paradoxical eczema in biologic-treated patients, and pyoderma gangrenosum during rituximab treatment.

The Surface Issue #12, April 2022 edition, was sent to all PSOLVE+ members by email on Tuesday, April 12th and can be accessed online here.

To view all issues of The Surface, go to psolve.org/the-surface

Updates from the 30th EADV Congress: Dr. Jonathan Levy reviews social media insights re. COVID-19 vaccination and biologic therapies, Canadian data on patients with anti-IL-17 therapy for psoriatic disease, and a comparison of biologic therapies from different classes. [Video 14 min]

In this 14-minute video, Dr. Jonathan Levy reviews social media insights re. COVID-19 vaccination and biologic therapies, Canadian data on patients with anti-IL-17 therapy for psoriatic disease, and a comparison of biologic therapies from different classes.


>> View the video (en anglais avec sous-titres français) [14 min 36 sec]

This video series was developed by a faculty of Canadian dermatologists from across Canada as part of the C2 Dermatology: Connect & Collaborate learning program. View all C2 Dermatology videos at psolve.org/c2-derm.

In compliance with Innovative Medicines Canada, this program is for Healthcare Professionals only, and is supported by Novartis Pharmaceuticals Canada.

Updates from the 30th EADV Congress: Dr. Gurbir Dhadwal reviews efficacy of TYK2 inhibitors, interruptions to secukinumab treatment, and a comparison of bimekizumab and secukinumab in different patient subgroups [Video 8 min]

In this 8-minute video, Dr. Gurbir Dhadwal reviews guidance from the 30th EADV Congress on efficacy of TYK2 inhibitors, interruptions to secukinumab treatment, and a comparison of bimekizumab and secukinumab in different patient subgroups.


>> View the video (en anglais avec sous-titres français) [8 min 27 sec]

This video series was developed by a faculty of Canadian dermatologists from across Canada as part of the C2 Dermatology: Connect & Collaborate learning program. View all C2 Dermatology videos at psolve.org/c2-derm.

In compliance with Innovative Medicines Canada, this program is for Healthcare Professionals only, and is supported by Novartis Pharmaceuticals Canada.

Updates from the 30th EADV Congress: Dr. Charles Lynde reviews guidance on how to recognize unmet needs of patients with CSU and translate key clinical trial evidence into practice [Video 10 min]

In this 10-minute video, Dr. Charles Lynde reviews guidance from the 30th EADV Congress on how to recognize unmet needs of patients with CSU and translate key clinical trial evidence into practice.


>> View the video (en anglais avec sous-titres français) [10 min 07 sec]

This video series was developed by a faculty of Canadian dermatologists from across Canada as part of the C2 Dermatology: Connect & Collaborate learning program. View all C2 Dermatology videos at psolve.org/c2-derm.

In compliance with Innovative Medicines Canada, this program is for Healthcare Professionals only, and is supported by Novartis Pharmaceuticals Canada.

Dr. Jessica Asgarpour reviews guidance from the 30th EADV Congress on how to recognize unmet needs and comorbidities, and improve the multidisciplinary care of patients with hidradenitis suppurativa [Video 12 min]

In this 12-minute video, Dr. Jessica Asgarpour reviews guidance from the 30th EADV Congress on how to recognize unmet needs and comorbidities, and improve the multidisciplinary care of patients with hidradenitis suppurativa.


>> View the video (en anglais avec sous-titres français) [12 min 40 sec]

This video series was developed by a faculty of Canadian dermatologists from across Canada as part of the C2 Dermatology: Connect & Collaborate learning program. View all C2 Dermatology videos at psolve.org/c2-derm.

In compliance with Innovative Medicines Canada, this program is for Healthcare Professionals only, and is supported by Novartis Pharmaceuticals Canada.

The Surface, Issue #11 is now available! We review the Phase 3 report on tapinarof cream, a safety study of halobetasol propionate’s effect on the HPA axis in a small group of adolescents, a case report of prurigo pigmentosa with new-onset diabetes, a look at skin cancers post-phototherapy, and an investigation into the transcriptome of psoriasis.

The Surface Issue #11, March 2022 edition, was sent to all PSOLVE+ members by email on March 10th and can be accessed online here.

To view all issues of The Surface, go to psolve.org/the-surface